Cancer immunotherapy company CEL-SCI Corporation (NYSE American:CVM) said on Monday that its underwriter Aegis Capital Corp has agreed to purchase, on a firm commitment basis, a minimum of 500,000 shares of its common stock of the company.
Aegis Capital Corp will purchase a minimum of 500,000 shares of common stock of the company at a price to the public of USD12.22 per share, representing a 5% discount to the closing price per share.
The company will provide the underwriter with a 45-day option to purchase up to 15% of the offering at the Public Price.
Proceeds will be used by the company to fund the continued development of Multikine, LEAPS as well as other general corporate purposes.
Closing of the offering is expected to occur on or about 26 March 2020, subject to customary closing conditions.
For the offering, Aegis Capital Corp is acting as the sole book-running manager.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories